Cartherics is pleased to announce that it has made several strategic new appointments to enhance its scientific and manufacturing teams, aligning with the company’s commitment to advancing its growing pipeline of innovative therapies. These new additions are expected to bring in diverse expertise, reinforcing the company’s capabilities in both research and development as well […]
Cartherics’ CEO, Prof. Alan Trounson, recently contributed to an insightful article in The Weekend Australian, exploring the latest advancements in cell therapy treatments for cancer. We would like to extend our thanks to Natasha Robinson for her thorough and thought-provoking piece that highlights how cell therapy breakthroughs are offering new hope to cancer […]
As Ovarian Cancer Awareness Month draws to a close, the Cartherics team gathered for an afternoon dedicated to raising awareness and funds for ovarian cancer research.
Each year, around 1,800 new ovarian cancer cases are diagnosed in Australia, with over 70% of these being at advanced stages and offering limited treatment options. Cartherics is developing innovative […]
Induced pluripotent stem cell (iPSC)-derived NK cells are revolutionising cancer immunotherapy by offering a scalable and reliable source of immune cells for therapeutic use. These NK cells are engineered to target and eliminate a wider range of tumours, providing new opportunities for treatment.
Unlike traditional donor-derived NK cells, iPSC-derived NK cells offer a limitless and consistent […]
Cartherics’ Chief Operating Officer, Dr. Ian Nisbet recently presented at the 3rd ANZ Biologics Festival at Crown Promenade in Melbourne. His presentation titled, ‘Building a Discovery-to-Clinic Company to Exploit the Full Power of Cell Therapies’ provided insights into Cartherics’ innovative approach to clinical manufacturing and cell therapy development.
The 3rd ANZ Biologics Festival brought together biopharma […]
In a recent article published in CGTLive, Cartherics’ Prof. Alan Trounson, Karl Trounson, Dr Walid Azar and Prof. Richard Boyd, together with Dr. Alice Pebay, Principal Research Fellow, The University of Melbourne and Royal Melbourne Hospital – discuss exciting developments in immunotherapy with natural killer (NK) cells.
As the cell therapy landscape continues to evolve, NK […]
Melbourne, Australia, 18 December 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), […]
As we reflect on 2024, it’s clear that this year has been a defining chapter in Cartherics’ 10-year history. We’ve experienced significant milestones, overcome challenges, and made bold strides toward advancing our mission. The work on ovarian cancer has progressed with the autologous CAR-T product under preclinical evaluation by the Peter MacCallum Cancer Centre, […]
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by BioSpectrum Asia discussing the development of the company’s cell-based immunotherapies for cancer treatment. The article discusses:
Cartherics is frocking up this October to raise funds and awareness for crucial ovarian cancer research. The current five-year survival rate for ovarian cancer patients is just 49%. There is no early detection test and treatment options haven’t improved significantly in decades.
Cartherics’ Board Advisor and ovarian cancer survivor Heather Hawkins said, “As a survivor, I hope to […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
